KR20160118345A - 6-헤테로아릴옥시- 및 6-아릴옥시-퀴놀린-2-카복사미드 및 이의 용도 - Google Patents

6-헤테로아릴옥시- 및 6-아릴옥시-퀴놀린-2-카복사미드 및 이의 용도 Download PDF

Info

Publication number
KR20160118345A
KR20160118345A KR1020167024669A KR20167024669A KR20160118345A KR 20160118345 A KR20160118345 A KR 20160118345A KR 1020167024669 A KR1020167024669 A KR 1020167024669A KR 20167024669 A KR20167024669 A KR 20167024669A KR 20160118345 A KR20160118345 A KR 20160118345A
Authority
KR
South Korea
Prior art keywords
oxy
pyridin
trifluoromethyl
alkyl
quinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167024669A
Other languages
English (en)
Korean (ko)
Inventor
앤드루 보그단
말론 디. 코워트
데이비드 에이. 데고이
태미 케이. 진케르슨
존 알. 코에닉
마이클 이. 코트
보 리우
마크 에이. 마툴렌코
데릭 더블유. 넬슨
미나 브이. 패텔
힐러리 펠티에
마르크 제이. 스캐니오
브라이언 디. 웨이크필드
Original Assignee
애브비 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애브비 인코포레이티드 filed Critical 애브비 인코포레이티드
Publication of KR20160118345A publication Critical patent/KR20160118345A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020167024669A 2014-02-06 2015-02-04 6-헤테로아릴옥시- 및 6-아릴옥시-퀴놀린-2-카복사미드 및 이의 용도 Withdrawn KR20160118345A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461936397P 2014-02-06 2014-02-06
US61/936,397 2014-02-06
PCT/US2015/014380 WO2015119998A1 (en) 2014-02-06 2015-02-04 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof

Publications (1)

Publication Number Publication Date
KR20160118345A true KR20160118345A (ko) 2016-10-11

Family

ID=52484589

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167024669A Withdrawn KR20160118345A (ko) 2014-02-06 2015-02-04 6-헤테로아릴옥시- 및 6-아릴옥시-퀴놀린-2-카복사미드 및 이의 용도

Country Status (14)

Country Link
US (3) US9452986B2 (enExample)
EP (1) EP3102569A1 (enExample)
JP (1) JP6532474B2 (enExample)
KR (1) KR20160118345A (enExample)
CN (1) CN106458985B (enExample)
AU (1) AU2015214366B2 (enExample)
BR (1) BR112016017996A2 (enExample)
CA (1) CA2938719A1 (enExample)
HK (1) HK1231471A1 (enExample)
IL (1) IL247014A0 (enExample)
MX (1) MX2016010056A (enExample)
RU (1) RU2016135637A (enExample)
SG (1) SG11201606367YA (enExample)
WO (1) WO2015119998A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
IL311677B2 (en) 2014-01-13 2025-06-01 Aurigene Oncology Ltd Bicyclic heterocyclyl derivatives as irak4 inhibitors
KR20160118345A (ko) * 2014-02-06 2016-10-11 애브비 인코포레이티드 6-헤테로아릴옥시- 및 6-아릴옥시-퀴놀린-2-카복사미드 및 이의 용도
US20170152263A1 (en) * 2014-06-20 2017-06-01 Aurigene Discovery Technologies Limited Substituted Indazole Compounds as IRAK4 Inhibitors
US9611262B2 (en) * 2014-09-11 2017-04-04 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
US10441586B2 (en) 2015-10-07 2019-10-15 Arizona Board Of Regents On Behalf Of The University Of Arizona CRMP2 SUMOylation inhibitors and uses thereof
SI3359541T1 (sl) * 2015-10-09 2021-01-29 Abbvie Overseas S.A R.L. N-sulfonirani pirazolo(3,4 b)piridin-6-karboksamidi in postopki uporabe
CN110337436A (zh) 2016-12-22 2019-10-15 拜耳作物科学股份公司 取代的1,2,4-噻二唑基吡咯酮和1,2,4-噻二唑基乙内酰脲及其盐及其作为除草剂的用途
WO2018178947A2 (en) 2017-03-31 2018-10-04 Aurigene Discovery Technologies Limited Compounds and compositions for treating hematological disorders
AU2018293627B2 (en) * 2017-06-30 2022-07-21 Elanco Animal Health Gmbh New azaquinoline derivatives
MY203827A (en) 2017-10-31 2024-07-19 Curis Inc Compounds and compositions for treating hematological disorders
KR102840599B1 (ko) 2018-07-09 2025-07-29 리버 인스티튜트, 아이엔씨 Nav1.8을 억제하기 위한 피리다진(PYRIDAZINE) 화합물
SG11202100130QA (en) 2018-07-09 2021-02-25 Lieber Institute Inc Pyridine carboxamide compounds for inhibiting nav1.8
HRP20241195T1 (hr) 2018-09-10 2024-11-22 Kaken Pharmaceutical Co., Ltd. Novi heteroaromatski amidni derivat i lijek koji ga sadrži
AU2019375983A1 (en) 2018-11-09 2021-06-10 Vivace Therapeutics, Inc. Bicyclic compounds
CN113784713A (zh) * 2019-01-11 2021-12-10 纳吉斯制药股份有限公司 白三烯合成抑制剂
EP3956033B1 (en) * 2019-04-16 2024-12-11 Vivace Therapeutics, Inc. Bicyclic compounds
AU2022254933A1 (en) 2021-04-08 2023-11-09 Curis, Inc. Combination therapies for the treatment of cancer
US20250115578A1 (en) * 2022-01-18 2025-04-10 Chengdu Kanghong Pharmaceutical Co., Ltd. Aromatic fused ring nav1.8 inhibitor, and use thereof
TW202434557A (zh) 2022-11-09 2024-09-01 瑞士商先正達農作物保護股份公司 殺微生物之吡唑衍生物
WO2025078263A1 (en) 2023-10-11 2025-04-17 Syngenta Crop Protection Ag Microbiocidal pyridyl pyrazole derivatives
WO2025233384A1 (en) 2024-05-08 2025-11-13 Syngenta Crop Protection Ag Microbiocidal pyrazole compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663994B1 (en) * 2003-08-05 2012-03-07 Vertex Pharmaceuticals Incorporated Tetrahydroquinazoline compounds as inhibitors of voltage-gated ion channels
KR100867071B1 (ko) * 2004-10-19 2008-11-04 에프. 호프만-라 로슈 아게 퀴놀린 유도체
CN101218226A (zh) * 2005-05-16 2008-07-09 沃泰克斯药物股份有限公司 作为离子通道调控剂的二环衍生物
GB0513692D0 (en) * 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
MX2008002731A (es) * 2005-09-01 2008-03-26 Hoffmann La Roche Diaminopirimidinas como moduladores de p2x3 y p3x2/3.
KR101402474B1 (ko) 2006-04-26 2014-06-19 제넨테크, 인크. 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물
MX2009003876A (es) * 2006-10-12 2009-05-11 Xenon Pharmaceuticals Inc Uso de compuestos de espiro-oxindol como agentes terapeuticos.
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
CN102448937A (zh) * 2009-05-29 2012-05-09 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
WO2011058766A1 (en) * 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
US8394829B2 (en) * 2010-05-10 2013-03-12 Gilead Sciences, Inc. Bi-functional quinoline analogs
RU2535671C1 (ru) * 2010-10-18 2014-12-20 Раквалиа Фарма Инк. Производные ариламидов в качестве блокаторов ttx-s
AR095192A1 (es) * 2013-01-31 2015-09-30 Vertex Pharma Quinolina y quinazolinamidas como modulares de canales de sodio
KR20160118345A (ko) * 2014-02-06 2016-10-11 애브비 인코포레이티드 6-헤테로아릴옥시- 및 6-아릴옥시-퀴놀린-2-카복사미드 및 이의 용도

Also Published As

Publication number Publication date
CN106458985A (zh) 2017-02-22
MX2016010056A (es) 2016-11-15
US20180334435A1 (en) 2018-11-22
US9452986B2 (en) 2016-09-27
US20150218102A1 (en) 2015-08-06
IL247014A0 (en) 2016-09-29
JP6532474B2 (ja) 2019-06-19
RU2016135637A (ru) 2018-03-12
CN106458985B (zh) 2019-05-03
AU2015214366A1 (en) 2016-08-18
WO2015119998A1 (en) 2015-08-13
US9969693B2 (en) 2018-05-15
US20160355482A1 (en) 2016-12-08
BR112016017996A2 (pt) 2017-08-08
AU2015214366B2 (en) 2019-04-18
HK1231471A1 (zh) 2017-12-22
EP3102569A1 (en) 2016-12-14
CA2938719A1 (en) 2015-08-13
US20170226062A9 (en) 2017-08-10
RU2016135637A3 (enExample) 2018-08-27
SG11201606367YA (en) 2016-09-29
JP2017505327A (ja) 2017-02-16

Similar Documents

Publication Publication Date Title
KR20160118345A (ko) 6-헤테로아릴옥시- 및 6-아릴옥시-퀴놀린-2-카복사미드 및 이의 용도
JP7041198B2 (ja) Ｊａｋ阻害剤である５－クロロ－２－ジフルオロメトキシフェニルピラゾロピリミジン化合物
KR101784977B1 (ko) ＴＲＫ 키나아제 억제제로서의 치환된 피라졸로 〔1,5-ａ〕피리미딘 화합물
CN107253963B (zh) 吡啶酮和氮杂吡啶酮化合物及使用方法
RU2689777C1 (ru) Конденсированные трициклические производные бензимидазолов в качестве модуляторов активности tnf
KR102085121B1 (ko) 이미다조[1,2-b]피리다진계 화합물, 그를 포함하는 조성물 및 그의 용도
KR20230167386A (ko) 옥사제핀 화합물 및 암 치료에서의 이의 사용
EP2178375B1 (en) Pyrazoloý1,5-a¨pyrimidine derivatives
JP6800885B2 (ja) イミダゾピラジン及びピラゾロピリミジン、並びにａｍｐａ受容体調節物質としてのこれらの使用
BR112015027055B1 (pt) Bi-heteroarilas, usos das mesmas, e composição farmacêutica
TW201726680A (zh) 作為IRAK4調節劑之吡唑并[1,5a]嘧啶衍生物
EP3717488B1 (en) Substituted furanopyrimidine compounds as pde1 inhibitors
WO2016065461A1 (en) Ripk2 inhibitors and method of treating cancer with same
CN120225531A (zh) 用于降解egfr激酶的化合物
JP2017508729A (ja) フロ−３−カルボキサミド誘導体および使用方法
EP3510030B1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
KR20200027994A (ko) Pde7 억제제로서 치환된 벤즈옥사졸 및 벤조푸란 화합물
CN115667251A (zh) 杂芳基衍生物化合物、及其用途
WO2023116779A1 (zh) 一种联炔类化合物及其应用
HK40036192B (en) Substituted furanopyrimidine compounds as pde1 inhibitors
HK40036192A (en) Substituted furanopyrimidine compounds as pde1 inhibitors
HK40031697A (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
HK40031697B (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
HK1219276B (zh) 二杂芳基化合物及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160906

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid